Skip to main content
Publications
Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.
Moehler M, Xiao H, Blum SI, Elimova E, Cella D, Shitara K, Ajani JA, Janjigian YY, Garrido M, Shen L, Yamaguchi K, Liu T, Schenker M, Kowalyszyn R, Bragagnoli AC, Bruges R, Montesarchio V, Pazo-Cid R, Hunter S, Davenport E, Wang J, Kondo K, Li M, Wyrwicz L. Health-Related quality of life with nivolumab plus chemotherapy versus chemotherapy in patients with advanced gastric/gastroesophageal junction cancer or esophageal adenocarcinoma from CheckMate 649. J Clin Oncol. 2023 Dec 10;41(35):5388-99. doi: 10.1200/JCO.23.00170
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer unselected for DDR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Niyazov A, Simou E, Kirker M, Houghton K, Le Moine JG, Chang J, Yarr S, Barnett C, Mladsi D. Pre-progression health state utility values from the TALAPRO-2 clinical trial in patients with metastatic castration-resistant prostate cancer with HRR mutations. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S149. doi: 10.1016/j.jval.2023.09.772
Drummond MF, Augustovski F, Bhattacharyya D, Campbell J, Chaiyakunapruk N, Chen Y, Galindo-Suarez RM, Guerino J, Mejia A, Mujoomdar M, Ollendorf D, Ronquest N, Torbica A, Tsiao E, Watkins J, Yeung K, ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems collaborators. Corrigendum to Challenges of health technology assessment in pluralistic healthcare systems: an ISPOR Council Report: [Value in Health 25 (2022) 1257-1267/3488]. Value Health. 2023 Dec;26(12):1811. doi: 10.1016/j.jval.2023.06.010
Boeri M, Marcek T, Chintakayala PK, Poulos C, Francis A, Langevin E, Balogh O, Petigara T, O’Connor J, Samant S. Preferences of nurses for attributes of pediatric hexavalent vaccines in the United Kingdom. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S313. doi: 10.1016/j.jval.2023.09.1653
Handels R, Herring W, Kamgar F, Gustavsson A, Skoldunger A, Wimo A, Tate A, Winblad B, Stellick CB, Bruck C, Green C, de Kok I, Hlavka J, Mar J, Urbich M, Soto-Gordoa M, Pemberton-Ross P, Aye S, Jonsson L, workshop 2023 Participants I. IPECAD modeling workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease and related dementias. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S419. doi: 10.1016/j.jval.2023.09.2194
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S549-50. doi: 10.1016/j.jval.2023.09.2953
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplment):S553. doi: 10.1016/j.jval.2023.09.2970
Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Poulos C, Gebben D, Peay H, Saha A, Vaezy S, Pierce A, Pina I, Farb A, Moultrie R, Babalola O, Tarver ME. Benefit-risk preferences of patients for the use of artificial intelligence and ultrasound imaging in different settings in echocardiography. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S349. doi: 10.1016/j.jval.2023.03.2378
Edwards T, Norcross L, Fine J, Martin S, Coulouvrat C, Spears P, Herold CI, Ferrari G, Onwudiwe N. Side effects and impacts of extended adjuvant endocrine therapy: a qualitative study among women with HR+/HER2- breast cancer. Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL. [abstract] J Clin Oncol. 2023 Jun; 41(Suppl 16):e12509. doi: 10.1200/JCO.2023.41.16_suppl.e12509